MiRNA-149 as a Candidate for Facial Clefting and Neural Crest Cell Migration.


Journal

Journal of dental research
ISSN: 1544-0591
Titre abrégé: J Dent Res
Pays: United States
ID NLM: 0354343

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 17 9 2021
medline: 16 3 2022
entrez: 16 9 2021
Statut: ppublish

Résumé

Nonsyndromic cleft lip with or without palate (nsCL/P) ranks among the most common human birth defects and has a multifactorial etiology. Human neural crest cells (hNCC) make a substantial contribution to the formation of facial bone and cartilage and are a key cell type in terms of nsCL/P etiology. Based on increasing evidence for the role of noncoding regulatory mechanisms in nsCL/P, we investigated the role of hNCC-expressed microRNAs (miRNA) in cleft development. First, we conducted a systematic analysis of miRNAs expressed in human-induced pluripotent stem cell-derived hNCC using Affymetrix microarrays on cell lines established from 4 unaffected donors. These analyses identified 152 candidate miRNAs. Based on the hypothesis that candidate miRNA loci harbor genetic variation associated with nsCL/P risk, the genomic locations of these candidates were cross-referenced with data from a previous genome-wide association study of nsCL/P. Associated variants were reanalyzed in independent nsCL/P study populations. Jointly, the results suggest that miR-149 is implicated in nsCL/P etiology. Second, functional follow-up included in vitro overexpression and inhibition of miR-149 in hNCC and subsequent analyses at the molecular and phenotypic level. Using 3'RNA-Seq, we identified 604 differentially expressed (DE) genes in hNCC overexpressing miR-149 compared with untreated cells. These included

Identifiants

pubmed: 34528480
doi: 10.1177/00220345211038203
doi:

Substances chimiques

MIRN149 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-330

Auteurs

L G Stüssel (LG)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

R Hollstein (R)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

M Laugsch (M)

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Institute of Human Genetics, CMMC, University Hospital Cologne, Cologne, Germany.

L M Hochfeld (LM)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

J Welzenbach (J)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

J Schröder (J)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

F Thieme (F)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

N Ishorst (N)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

R Olmos Romero (RO)

Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Institute of Human Genetics, CMMC, University Hospital Cologne, Cologne, Germany.

L Weinhold (L)

Institute of Medical Biometry Informatics and Epidemiology, University of Bonn, Bonn, Germany.

T Hess (T)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.
Center of Human Genetics, University Hospital of Marburg, Marburg, Germany.

J Gehlen (J)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.
Center of Human Genetics, University Hospital of Marburg, Marburg, Germany.

A Mostowska (A)

Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland.

S Heilmann-Heimbach (S)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

E Mangold (E)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

A Rada-Iglesias (A)

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Institute of Biomedicine and Biotechnology, University of Cantabria, Santander, Spain.

M Knapp (M)

Institute of Medical Biometry Informatics and Epidemiology, University of Bonn, Bonn, Germany.

C P Schaaf (CP)

Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Institute of Human Genetics, CMMC, University Hospital Cologne, Cologne, Germany.

K U Ludwig (KU)

Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH